Home › Companies › AGIOS PHARMACEUTICALS INC. › 2024-2025
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and AGIOS PHARMACEUTICALS INC.’s Form 8-K, filed June 18, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 18, 2025: 5 items on AGIOS PHARMACEUTICALS INC.’s Form 8-K, filed June 18, 2025: 3 approved · 2 passed (calculated).
Notable dissent: 1 other board item (36.5% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore AGIOS PHARMACEUTICALS INC. in the interactive database Compare manager voting policies
These tallies are AGIOS PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 18, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Jacqualyn A. Fouse, Ph.D. | 45,959,402 | -- | -- | 3,925,859 | 1,475,062 | 92% | Passed (calculated) | — |
| Elect Director: David Scadden, M.D. | 46,204,689 | -- | -- | 3,680,572 | 1,475,062 | 93% | Passed (calculated) | — |
| 2. Company's stockholders approved the non-binding, advisory vote on the compensation paid to its named executive officers. | 46,843,926 | 3,024,905 | 16,430 | -- | 1,475,062 | 94% | Approved | — |
| 3. Company's stockholders approved the 2023 Plan Amendment. | 31,683,420 | 18,197,324 | 4,517 | -- | 1,475,062 | 64% | Approved | — |
| 4. Company's stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the current fiscal year. | 51,200,808 | 136,734 | 22,781 | -- | 0 | 99.7% | Approved | — |
Source: AGIOS PHARMACEUTICALS INC., Form 8-K, filed with the SEC on June 18, 2025 — read the filing on EDGAR.
See voting trends for Health Care companies, 2024-2025: shareholder support by sector and by company size.
248 asset managers disclosed a vote on at least one AGIOS PHARMACEUTICALS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 3 wordings of this item as funds reported it.
93% Majority: yes · of votes cast
Description as filed by funds: To elect each of the two Class III director nominees set forth in the Proxy Statement, each to serve for a three-year term expiring at the 2028 annual meeting of stockholders and until his or her respective successor is duly elected and qualified: David Scadden, M.D.
AGIOS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: David Scadden, M.D.”): 46,204,689 for, 3,680,572 withheld, per its Form 8-K filed June 18, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 93% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,116,254 | 0 | 0 | 0 | For |
| BlackRock | 2,553,677 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,751,483 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 1,537,387 | 0 | 0 | 0 | For |
| Fidelity | 1,536,298 | 0 | 0 | 0 | For |
| State Street | 4,835 | 0 | 0 | 1,151,992 | Withhold |
| Charles Schwab | 473,555 | 0 | 0 | 0 | For |
| JPMorgan | 352,509 | 0 | 0 | 0 | For |
| Artisan | 280,695 | 0 | 0 | 0 | For |
| AMG FUNDS | 196,273 | 0 | 0 | 0 | For |
| Equitable | 106,768 | 0 | 0 | 60,110 | Mixed |
| TIAA | 151,019 | 0 | 0 | 0 | For |
| MERIDIAN FUND INC | 147,936 | 0 | 0 | 0 | For |
| American Century | 120,474 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 96,562 | 0 | 0 | 0 | For |
| WisdomTree | 90,637 | 0 | 0 | 0 | For |
| Northern Trust | 64,334 | 0 | 0 | 0 | For |
| Goldman Sachs | 61,531 | 0 | 0 | 0 | For |
| Lincoln Financial | 19,674 | 0 | 0 | 41,500 | Mixed |
| GuideStone | 55,647 | 0 | 0 | 0 | For |
| Invesco | 0 | 0 | 0 | 54,918 | Withhold |
| Brighthouse | 51,460 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 50,585 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 47,331 | 0 | 0 | 0 | For |
| John Hancock | 43,928 | 0 | 0 | 0 | For |
Fund voting reports, all 73 managers: 16,559,197 for, 1,313,512 withheld, 0 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Erste Asset Management GmbH | 2,304,900 | 0 | 0 | 0 | For |
Institutional-manager reports, all 1 managers: 2,304,900 for.
Combines 3 wordings of this item as funds reported it.
92% Majority: yes · of votes cast
Description as filed by funds: To elect each of the two Class III director nominees set forth in the Proxy Statement, each to serve for a three-year term expiring at the 2028 annual meeting of stockholders and until his or her respective successor is duly elected and qualified: Jacqualyn A. Fouse, Ph.D.
AGIOS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Jacqualyn A. Fouse, Ph.D.”): 45,959,402 for, 3,925,859 withheld, per its Form 8-K filed June 18, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 92% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,115,777 | 0 | 0 | 477 | For |
| BlackRock | 2,553,677 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,751,483 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 1,537,387 | 0 | 0 | 0 | For |
| Fidelity | 1,536,298 | 0 | 0 | 0 | For |
| State Street | 4,812 | 0 | 0 | 1,152,015 | Withhold |
| Charles Schwab | 473,555 | 0 | 0 | 0 | For |
| JPMorgan | 352,509 | 0 | 0 | 0 | For |
| Artisan | 280,695 | 0 | 0 | 0 | For |
| AMG FUNDS | 196,273 | 0 | 0 | 0 | For |
| Equitable | 106,768 | 0 | 0 | 60,110 | Mixed |
| TIAA | 151,019 | 0 | 0 | 0 | For |
| MERIDIAN FUND INC | 147,936 | 0 | 0 | 0 | For |
| American Century | 120,474 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 96,562 | 0 | 0 | 0 | For |
| WisdomTree | 90,637 | 0 | 0 | 0 | For |
| Northern Trust | 64,334 | 0 | 0 | 0 | For |
| Goldman Sachs | 61,531 | 0 | 0 | 0 | For |
| Lincoln Financial | 19,674 | 0 | 0 | 41,500 | Mixed |
| GuideStone | 55,647 | 0 | 0 | 0 | For |
| Invesco | 54,918 | 0 | 0 | 0 | For |
| Brighthouse | 51,460 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 50,585 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 47,331 | 0 | 0 | 0 | For |
| John Hancock | 43,928 | 0 | 0 | 0 | For |
Fund voting reports, all 73 managers: 16,591,020 for, 1,281,689 withheld, 0 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Erste Asset Management GmbH | 0 | 2,304,900 | 0 | 0 | Against |
Institutional-manager reports, all 1 managers: 2,304,900 against.
Combines 2 wordings of this item as funds reported it.
64% Approved · of votes cast
Description as filed by funds: TO APPROVE AN AMENDMENT TO THE AGIOS PHARMACEUTICALS, INC. 2023 STOCK INCENTIVE PLAN, TO INCREASE THE NUMBER OF SHARES OF COMMON STOCK AVAILABLE THEREUNDER BY 2,500,000 SHARES.
AGIOS PHARMACEUTICALS INC.’s own tally for this item (“3. The Company's stockholders approved the 2023 Plan Amendment.”): 31,683,420 for, 18,197,324 against — passed, per its Form 8-K filed June 18, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved the 2023 Plan Amendment.”
Support: 64% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Also reported under other wordings, matched to the same row of AGIOS PHARMACEUTICALS INC.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Amend Omnibus Stock Plan” (4 managers, Fund and manager reports combined; may count the same shares twice; no share total shown).
The 72 asset managers below reported 14,955,332 for, 2,881,395 against, 1,894 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,112,654 | 3,600 | 0 | 0 | For |
| BlackRock | 2,553,677 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,751,483 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 0 | 1,537,387 | 0 | 0 | Against |
| Fidelity | 1,294,335 | 241,963 | 0 | 0 | Mixed |
| State Street | 1,155,331 | 1,496 | 0 | 0 | For |
| Charles Schwab | 473,555 | 0 | 0 | 0 | For |
| JPMorgan | 352,509 | 0 | 0 | 0 | For |
| Artisan | 0 | 280,695 | 0 | 0 | Against |
| AMG FUNDS | 0 | 196,273 | 0 | 0 | Against |
| Equitable | 166,878 | 0 | 0 | 0 | For |
| TIAA | 151,019 | 0 | 0 | 0 | For |
| MERIDIAN FUND INC | 147,936 | 0 | 0 | 0 | For |
| American Century | 0 | 120,474 | 0 | 0 | Against |
| QUANTITATIVE MASTER SERIES LLC | 96,562 | 0 | 0 | 0 | For |
| WisdomTree | 90,637 | 0 | 0 | 0 | For |
| Northern Trust | 64,334 | 0 | 0 | 0 | For |
| Goldman Sachs | 47,555 | 13,976 | 0 | 0 | Mixed |
| Lincoln Financial | 41,500 | 19,674 | 0 | 0 | Mixed |
| Invesco | 54,918 | 0 | 0 | 0 | For |
| Brighthouse | 31,140 | 20,320 | 0 | 0 | Mixed |
| Columbia Threadneedle | 0 | 50,585 | 0 | 0 | Against |
| Direxion Shares ETF Trust | 0 | 47,331 | 0 | 0 | Against |
| John Hancock | 23,868 | 20,060 | 0 | 0 | Mixed |
| ALPS ETF Trust | 0 | 42,419 | 0 | 0 | Against |
Showing the 25 largest of 72 asset managers. All 72 are in the interactive database (link above).
Combines 9 wordings of this item as funds reported it.
94% Approved · of votes cast
Prior year: 93.9% for (June 20, 2024 meeting) unchanged
Description as filed by funds: To vote, on an advisory basis, to approve the compensation paid to our named executive officers.
AGIOS PHARMACEUTICALS INC.’s own tally for this item (“2. The Company's stockholders approved the non-binding, advisory vote on the compensation paid to its named executive officers.”): 46,843,926 for, 3,024,905 against — passed, per its Form 8-K filed June 18, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved the non-binding, advisory vote on the compensation paid to its named executive officers.”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,115,777 | 477 | 0 | 0 | For |
| BlackRock | 2,553,677 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,751,483 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 1,537,387 | 0 | 0 | 0 | For |
| Fidelity | 1,536,298 | 0 | 0 | 0 | For |
| State Street | 1,156,827 | 0 | 0 | 0 | For |
| Charles Schwab | 473,555 | 0 | 0 | 0 | For |
| JPMorgan | 352,509 | 0 | 0 | 0 | For |
| Artisan | 280,695 | 0 | 0 | 0 | For |
| AMG FUNDS | 196,273 | 0 | 0 | 0 | For |
| Equitable | 166,878 | 0 | 0 | 0 | For |
| TIAA | 151,019 | 0 | 0 | 0 | For |
| MERIDIAN FUND INC | 147,936 | 0 | 0 | 0 | For |
| American Century | 0 | 120,474 | 0 | 0 | Against |
| QUANTITATIVE MASTER SERIES LLC | 96,562 | 0 | 0 | 0 | For |
| WisdomTree | 90,637 | 0 | 0 | 0 | For |
| Northern Trust | 64,334 | 0 | 0 | 0 | For |
| Goldman Sachs | 61,531 | 0 | 0 | 0 | For |
| Lincoln Financial | 61,174 | 0 | 0 | 0 | For |
| GuideStone | 55,647 | 0 | 0 | 0 | For |
| Invesco | 0 | 54,918 | 0 | 0 | Against |
| Brighthouse | 51,460 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 0 | 50,585 | 0 | 0 | Against |
| Direxion Shares ETF Trust | 47,331 | 0 | 0 | 0 | For |
| John Hancock | 43,928 | 0 | 0 | 0 | For |
Fund voting reports, all 73 managers: 17,644,361 for, 226,454 against, 1,894 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| FARALLON CAPITAL MANAGEMENT LLC | 5,072,130 | 0 | 0 | 0 | For |
| Erste Asset Management GmbH | 2,304,900 | 0 | 0 | 0 | For |
| Commodore Capital LP | 2,291,637 | 0 | 0 | 0 | For |
| T. Rowe Price | 2,288,768 | 0 | 0 | 0 | For |
| State Street | 2,273,044 | 0 | 0 | 0 | For |
| BlackRock | 2,068,213 | 0 | 0 | 0 | For |
| MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST | 1,694,299 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,406,164 | 0 | 0 | 0 | For |
| Frazier Life Sciences Management, L.P. | 1,279,754 | 0 | 0 | 0 | For |
| BNP Paribas Asset Management Holding S.A. | 0 | 964,812 | 0 | 0 | Against |
| JPMorgan | 921,632 | 0 | 0 | 0 | For |
| Fisher Asset Management, LLC | 855,721 | 0 | 0 | 0 | For |
| GW&K Investment Management, LLC | 252,139 | 0 | 0 | 0 | For |
| ArrowMark Colorado Holdings LLC | 772,307 | 0 | 0 | 0 | For |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 743,000 | 0 | 0 | 0 | For |
| Caligan Partners LP | 578,827 | 0 | 0 | 0 | For |
| SCS Capital Management LLC | 551,348 | 0 | 0 | 0 | For |
| Charles Schwab | 473,555 | 0 | 0 | 0 | For |
| Northern Trust | 454,460 | 0 | 0 | 0 | For |
| Artisan | 375,277 | 0 | 0 | 0 | For |
| Rock Springs Capital Management LP | 342,180 | 0 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 299,262 | 0 | 0 | 0 | For |
| ORBIMED ADVISORS LLC | 271,022 | 0 | 0 | 0 | For |
| NORDEA INVESTMENT MANAGEMENT AB | 0 | 230,164 | 0 | 0 | Against |
| AXA INVESTMENT MANAGERS UK Ltd | 0 | 225,119 | 0 | 0 | Against |
Institutional-manager reports, all 194 managers: 30,444,875 for, 1,930,721 against, 538,079 mixed. Showing the 25 largest; every one is in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
99.7% Approved · of votes cast
Prior year: 99.9% for (June 20, 2024 meeting) ▼ 0.1 pts
Description as filed by funds: To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.
AGIOS PHARMACEUTICALS INC.’s own tally for this item (“4. The Company's stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the current fiscal year.”): 51,200,808 for, 136,734 against — passed, per its Form 8-K filed June 18, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the current fiscal year.”
Support: 99.7% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,116,254 | 0 | 0 | 0 | For |
| BlackRock | 2,553,677 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,751,483 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 1,537,387 | 0 | 0 | 0 | For |
| Fidelity | 1,536,298 | 0 | 0 | 0 | For |
| State Street | 1,156,758 | 69 | 0 | 0 | For |
| Charles Schwab | 473,555 | 0 | 0 | 0 | For |
| JPMorgan | 352,509 | 0 | 0 | 0 | For |
| Artisan | 280,695 | 0 | 0 | 0 | For |
| AMG FUNDS | 196,273 | 0 | 0 | 0 | For |
| Equitable | 166,878 | 0 | 0 | 0 | For |
| TIAA | 151,019 | 0 | 0 | 0 | For |
| MERIDIAN FUND INC | 147,936 | 0 | 0 | 0 | For |
| American Century | 120,474 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 96,562 | 0 | 0 | 0 | For |
| WisdomTree | 90,637 | 0 | 0 | 0 | For |
| Northern Trust | 64,334 | 0 | 0 | 0 | For |
| Goldman Sachs | 61,531 | 0 | 0 | 0 | For |
| Lincoln Financial | 61,174 | 0 | 0 | 0 | For |
| GuideStone | 55,647 | 0 | 0 | 0 | For |
| Invesco | 54,918 | 0 | 0 | 0 | For |
| Brighthouse | 51,460 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 50,585 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 47,331 | 0 | 0 | 0 | For |
| John Hancock | 43,928 | 0 | 0 | 0 | For |
Fund voting reports, all 73 managers: 17,854,064 for, 16,751 against, 1,894 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Erste Asset Management GmbH | 2,304,900 | 0 | 0 | 0 | For |
Institutional-manager reports, all 1 managers: 2,304,900 for.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 57,886,781 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 10.57% |
| 2 | BlackRock | 4.41% |
| 3 | T. Rowe Price | 3.03% |
| 4 | Delaware/Macquarie | 2.66% |
| 5 | Fidelity | 2.65% |
| 6 | State Street | 2.00% |
| 7 | Charles Schwab | 0.82% |
| 8 | JPMorgan | 0.61% |
| 9 | Artisan | 0.48% |
| 10 | AMG FUNDS | 0.34% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | FARALLON CAPITAL MANAGEMENT LLC | 8.76% |
| 2 | Erste Asset Management GmbH | 3.98% |
| 3 | Commodore Capital LP | 3.96% |
| 4 | T. Rowe Price | 3.95% |
| 5 | State Street | 3.93% |
| 6 | BlackRock | 3.57% |
| 7 | MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST | 2.93% |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 2.43% |
| 9 | Frazier Life Sciences Management, L.P. | 2.21% |
| 10 | BNP Paribas Asset Management Holding S.A. | 1.67% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| Vanguard Group | 5,604,591 | 9.68% | Form 13F, quarter ended March 31, 2025 |
| BlackRock | 5,108,746 | 8.83% | Form 13F, quarter ended March 31, 2025 |
| Farallon Partners, L.L.C. | 5,046,401 | 8.72% | Schedule 13G, filed February 9, 2026 |
| Lynx1 Capital Management LP | 3,013,949 | 5.21% | Schedule 13G, filed May 6, 2026 |
| State Street | 2,449,479 | 4.23% | Form 13F, quarter ended March 31, 2025 |
| T. Rowe Price | 2,301,353 | 3.98% | Form 13F, quarter ended March 31, 2025 |
| Geode Capital | 1,394,581 | 2.41% | Form 13F, quarter ended March 31, 2025 |
| Dimensional Fund Advisors | 1,262,073 | 2.18% | Form 13F, quarter ended March 31, 2025 |
| JPMorgan Chase | 1,049,360 | 1.81% | Form 13F, quarter ended March 31, 2025 |
| Goldman Sachs | 658,652 | 1.14% | Form 13F, quarter ended March 31, 2025 |
Percentages above are of 57,886,781 shares outstanding, as reported by AGIOS PHARMACEUTICALS INC. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At AGIOS PHARMACEUTICALS INC.'s shareholder meeting held June 18, 2025, in the 2024-2025 proxy season, 248 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 1,396 separate fund positions. On the most widely held item on that ballot — To vote, on an advisory basis, to approve the compensation paid to our named executive officers. — AGIOS PHARMACEUTICALS INC.'s filing reports the proposal as approved, with 94% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: AGIOS PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 18, 2025.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from AGIOS PHARMACEUTICALS INC.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
AGIOS PHARMACEUTICALS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.
Proxy Votes Now, “AGIOS PHARMACEUTICALS (AGIO) 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/agios-pharmaceuticals-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.